Clinical effectiveness of pharmacogenomic-guided antidepressant treatment in adult major depressive disorder: systematic review and exploratory platform-aware meta-analysis.
Ilaria Pullano, Anna Maria Iazzolino, Chiara Di Lorenzo et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and exploratory meta-analysis evaluated the effectiveness of pharmacogenomic-guided antidepressant treatment in adults with major depressive disorder (MDD). The analysis included eight randomized controlled trials (RCTs). The GeneSight-guided care showed a 30% increase in response and a 53% increase in remission rates compared to treatment as usual within 8-12 weeks.
Key findings
- GeneSight-guided care increased response rates by 30% (RR 1.30, 95% CI 1.09-1.56).
- Remission rates improved by 53% with GeneSight-guided care (RR 1.53, 95% CI 1.19-1.97).
- Cross-platform analysis showed heterogeneous effects for response (RR 1.18, 95% CI 0.91-1.54).
- Remission rates in the cross-platform analysis were also heterogeneous (RR 1.18, 95% CI 0.77-1.80).
Why it matters
Understanding the effectiveness of pharmacogenomic-guided treatment can help clinicians make informed decisions about antidepressant prescribing, potentially improving patient outcomes in major depressive disorder.
What to keep in mind
The evidence was limited by the small number of short-term RCTs and concerns regarding risk of bias and heterogeneity in the exploratory analysis.